| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | 0.07 | 0.06 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | -0.07 | 0.06 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.06 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.094 | 0.06 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | 0.097 | 0.06 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | -0.095 | 0.06 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.07 | 0.06 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.07 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.061 | 0.07 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | 0.091 | 0.07 |